정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
1801 | Recruiting | COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations | Mast Cell Disorder | Biological: Moderna COVID-19 Vaccine Biological: Pfizer-BioNTech COVID-19 Vaccine Biological: Placebo |
Phase 2 | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Rho Federal Systems Division, Inc. | NIH | 3400 | All | 12 Years | University of Arizona Health Sciences, College of Medicine Tucson, Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Tucson, Arizona, United States Arkansas Children's, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States University of California, Los Angeles Medical Center, Los Angeles, California, United States Stanford Medicine, Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, United States National Jewish Health, Denver, Colorado, United States University Health, University of Miami Health System, Miami, Florida, United States University of South Florida Asthma Allergy and Immunology Clinical Research Unit, Tampa, Florida, United States Emory University School of Medicine, Emory Healthcare: Emory Clinic Allergy and Immunology, Atlanta, Georgia, United States Sinus and Allergy Center of Northwestern University, Chicago, Illinois, United States NorthShore University HealthSystem, Dermatology Clinical Trials Unit, Skokie, Illinois, United States University of Iowa Health Care, Iowa City, Iowa, United States Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States Massachusetts General Hospital, Boston, Massachusetts, United States Brigham and Women's Hospital, Boston, Massachusetts, United States University of Michigan Health, Ann Arbor, Michigan, United States Henry Ford Hospital and Health System, Detroit, Michigan, United States Saint Louis University Care Center for Specialized Medicine, Saint Louis, Missouri, United States Mount Sinai Hospital, Department of Medicine, Division of Clinical Immunology, New York, New York, United States Columbia University Irving Medical Center, New York, New York, United States Rochester Regional Health, Rochester, New York, United States North Carolina Translational and Clinical Sciences Institute-Clinical & Translational Research Center (CTRC) at the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States Cleveland Clinic, Allergy & Clinical Immunology, Cleveland, Ohio, United States Penn State Health Allergy, Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States Vanderbilt University Medical Center, Nashville, Tennessee, United States University of Texas Southwestern Medical Center, Dallas, Texas, United States Baylor College of Medicine Medical Center, Houston, Texas, United States University of Virginia Health System: Department of Medicine, Division of Allergy and Immunology, Charlottesville, Virginia, United States Virginia Commonwealth University, Department of Internal Medicine, Division of Rheumatology, Allergy & Immunology, Richmond, Virginia, United States University of Wisconsin Asthma Allergy Pulmonary Research, Madison, Wisconsin, United States |
1800 | Recruiting | COVID-19 Serology and Immunosenescence | Immunosenescence | Biological: blood sample | Not Applicable | Centre Hospitalier Universitaire, Amiens | OTHER | 330 | All | 18 Years | CHU Amiens, Amiens, France |
1799 | Active, not recruiting | COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo) | Pneumonia | Biological: COVID-19 Specific T Cell derived exosomes (CSTC-Exo) | Phase 1 | TC Erciyes University | OTHER | 60 | All | 18 Years ~ 75 Years | GENKOK, Kayseri, Melikgazi, Turkey |
1798 | Completed | COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay | Healthy Participants | Drug: REGN10933 + REGN10987 Drug: Placebo |
Phase 3 | Regeneron Pharmaceuticals | INDUSTRY | 3303 | All | Regeneron Study Site, Mesa, Arizona, United States Regeneron Study Site, Tucson, Arizona, United States Regeneron Study Site, Tucson, Arizona, United States Regeneron Study Site, La Mesa, California, United States Regeneron Study Site, La Palma, California, United States Regeneron Study Site, Long Beach, California, United States Regeneron Study Site, Los Angeles, California, United States Regeneron Study Site, Los Angeles, California, United States Regeneron Study Site, Los Angeles, California, United States Regeneron Study Site, Montclair, California, United States Regeneron Study Site, Northridge, California, United States Regeneron Study Site, Oxnard, California, United States Regeneron Study Site, Sacramento, California, United States Regeneron Study Site, Sacramento, California, United States Regeneron Study Site, San Diego, California, United States Regeneron Study Site, San Francisco, California, United States Regeneron Study Site, Stanford, California, United States Regeneron Study Site, Torrance, California, United States Regeneron Study Site, Torrance, California, United States Regeneron Study Site, Aurora, Colorado, United States Regeneron Study Site, Colorado Springs, Colorado, United States Regeneron Study Site, Washington, District of Columbia, United States Regeneron Study Site, Boca Raton, Florida, United States Regeneron Study Site, Clearwater, Florida, United States Regeneron Study Site, DeLand, Florida, United States Regeneron Study Site, Fort Pierce, Florida, United States Regeneron Study Site, Hialeah, Florida, United States Regeneron Study Site, Jacksonville, Florida, United States Regeneron Study Site, Lakeland, Florida, United States Regeneron Study Site, Loxahatchee Groves, Florida, United States Regeneron Study Site, Maitland, Florida, United States Regeneron Study Site, Miami, Florida, United States Regeneron Study Site, Miami, Florida, United States Regeneron Study Site, Miami, Florida, United States Regeneron Study Site, Miami, Florida, United States Regeneron Study Site, Miami, Florida, United States Regeneron Study Site, Miami, Florida, United States Regeneron Study Site, Miami, Florida, United States Regeneron Study Site, Orlando, Florida, United States Regeneron Study Site, Sarasota, Florida, United States Regeneron Study Site, Tampa, Florida, United States Regeneron Study Site, West Palm Beach, Florida, United States Regeneron Study Site, Winter Park, Florida, United States Regeneron Study Site, Atlanta, Georgia, United States Regeneron Study Site, Atlanta, Georgia, United States Regeneron Study Site, Columbus, Georgia, United States Regeneron Study Site, Decatur, Georgia, United States Regeneron Study Site, Eatonton, Georgia, United States Regeneron Study Site, Marietta, Georgia, United States Regeneron Study Site, Sandy Springs, Georgia, United States Regeneron Study Site, Chicago, Illinois, United States Regeneron Study Site 2, Chicago, Illinois, United States Regeneron Study Site 3, Chicago, Illinois, United States Regeneron Study Site, Chicago, Illinois, United States Regeneron Study Site 1, Downers Grove, Illinois, United States Regeneron Study Site 2, Downers Grove, Illinois, United States Regeneron Study Site, Ames, Iowa, United States Regeneron Study Site, Lake Charles, Louisiana, United States Regeneron Study Site, Marrero, Louisiana, United States Regeneron Study Site, Metairie, Louisiana, United States Regeneron Study Site, New Orleans, Louisiana, United States Regeneron Study Site, Baltimore, Maryland, United States Regeneron Study Site, Boston, Massachusetts, United States Regeneron Study Site, Boston, Massachusetts, United States Regeneron Study Site, Boston, Massachusetts, United States Regeneron Study Site, Boston, Massachusetts, United States Regeneron Study Site, Boston, Massachusetts, United States Regeneron Study Site, Detroit, Michigan, United States Regeneron Study Site, Royal Oak, Michigan, United States Regeneron Study Site, Minneapolis, Minnesota, United States Regeneron Study Site, Gulfport, Mississippi, United States Regeneron Study Site, Jackson, Mississippi, United States Regeneron Study Site, Hazelwood, Missouri, United States Regeneron Study Site, Saint Louis, Missouri, United States Regeneron Study Site, Las Vegas, Nevada, United States Regeneron Study Site, Las Vegas, Nevada, United States Regeneron Study Site, Morristown, New Jersey, United States Regeneron Study Site, Newark, New Jersey, United States Regeneron Study Site, Summit, New Jersey, United States Regeneron Study Site, Teaneck, New Jersey, United States Regeneron Study Site 1, Bronx, New York, United States Regeneron Study Site 2, Bronx, New York, United States Regeneron Study Site, Bronx, New York, United States Regeneron Study Site, Buffalo, New York, United States Regeneron Study Site, New York, New York, United States Regeneron Study Site, New York, New York, United States Regeneron Study Site, New York, New York, United States Regeneron Study Site, New York, New York, United States Regeneron Study Site, New York, New York, United States Regeneron Study Site, New York, New York, United States Regeneron Study Site, Chapel Hill, North Carolina, United States Regeneron Study Site, Charlotte, North Carolina, United States Regeneron Study Site, Fayetteville, North Carolina, United States Regeneron Study Site, Raleigh, North Carolina, United States Regeneron Study Site, Wilmington, North Carolina, United States Regeneron Study Site, Winston-Salem, North Carolina, United States Regeneron Study Site, Cincinnati, Ohio, United States Regeneron Study Site, Columbus, Ohio, United States Regeneron Study Site, Columbus, Ohio, United States Regeneron Study Site, Dayton, Ohio, United States Regeneron Study Site, Danville, Pennsylvania, United States Regeneron Study Site, Philadelphia, Pennsylvania, United States Regeneron Study Site, Philadelphia, Pennsylvania, United States Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States Regeneron Study Site, Providence, Rhode Island, United States Regeneron Study Site, Charleston, South Carolina, United States Regeneron Study Site, Charleston, South Carolina, United States Regeneron Study Site, Clinton, South Carolina, United States Regeneron Study Site, Gaffney, South Carolina, United States Regeneron Study Site, Sioux Falls, South Dakota, United States Regeneron Study Site, Chattanooga, Tennessee, United States Regeneron Study Site, Knoxville, Tennessee, United States Regeneron Study Site, Memphis, Tennessee, United States Regeneron Study Site, Nashville, Tennessee, United States Regeneron Study Site, Bellaire, Texas, United States Regeneron Study Site, Corpus Christi, Texas, United States Regeneron Study Site, Dallas, Texas, United States Regeneron Study Site, Houston, Texas, United States Regeneron Study Site, Houston, Texas, United States Regeneron Study Site, Houston, Texas, United States Regeneron Study Site, Houston, Texas, United States Regeneron Study Site, Houston, Texas, United States Regeneron Study Site, Pearland, Texas, United States Regeneron Study Site, Red Oak, Texas, United States Regeneron Study Site, San Antonio, Texas, United States Regeneron Study Site, Tyler, Texas, United States Regeneron Study Site, Charlottesville, Virginia, United States Regeneron Study Site, Richmond, Virginia, United States Regeneron Study Site, Everett, Washington, United States Regeneron Study Site, Seattle, Washington, United States Regeneron Study Site, Yakima, Washington, United States Regeneron Study Site, Madison, Wisconsin, United States Regeneron Study Site, Chisinau, Moldova, Republic of Regeneron Study Site, Bucharest, Romania |
|
1797 | Completed | COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection | COVID-19 | Drug: REGN10933+REGN10987 combination therapy Drug: Placebo |
Phase 2 | Regeneron Pharmaceuticals | INDUSTRY | 1164 | All | 18 Years | Regeneron Study Site, Mesa, Arizona, United States Regeneron Study Site, Tucson, Arizona, United States Regeneron Study Site, Canoga Park, California, United States Regeneron Study Site, Long Beach, California, United States Regeneron Study Site, Los Angeles, California, United States Regeneron Study Site, Rolling Hills Estates, California, United States Regeneron Study Site, San Francisco, California, United States Regeneron Study Site, Santa Monica, California, United States Regeneron Study Site, Stanford, California, United States Regeneron Study Site, Colorado Springs, Colorado, United States Regeneron Study Site, Washington, District of Columbia, United States Regeneron Study Site, DeLand, Florida, United States Regeneron Study Site, Fort Pierce, Florida, United States Regeneron Study Site, Hialeah, Florida, United States Regeneron Study Site, Hialeah, Florida, United States Regeneron Study Site, Maitland, Florida, United States Regeneron Study Site, Miami, Florida, United States Regeneron Study Site, Miami, Florida, United States Regeneron Study Site, Saint Petersburg, Florida, United States Regeneron Study Site, Tampa, Florida, United States Regeneron Study Site, West Palm Beach, Florida, United States Regeneron Study Site, Winter Haven, Florida, United States Regeneron Study Site, Winter Park, Florida, United States Regeneron Study Site, Atlanta, Georgia, United States Regeneron Study Site, Columbus, Georgia, United States Regeneron Study Site, Downers Grove, Illinois, United States Regeneron Study Site, Ames, Iowa, United States Regeneron Study Site, Iowa City, Iowa, United States Regeneron Study Site, Lake Charles, Louisiana, United States Regeneron Study Site, Marrero, Louisiana, United States Regeneron Study Site, Shreveport, Louisiana, United States Regeneron Study Site, Baltimore, Maryland, United States Regeneron Study Site, Las Vegas, Nevada, United States Regeneron Study Site, Teaneck, New Jersey, United States Regeneron Study Site, Bronx, New York, United States Regeneron Study Site, New York, New York, United States Regeneron Study Site, Charlotte, North Carolina, United States Regeneron Study Site, Durham, North Carolina, United States Regeneron Study Site, Wilmington, North Carolina, United States Regeneron Study Site, Columbus, Ohio, United States Regeneron Study Site, Dayton, Ohio, United States Regeneron Study Site, Dayton, Ohio, United States Regeneron Study Site, Philadelphia, Pennsylvania, United States Regeneron Study Site, Charleston, South Carolina, United States Regeneron Study Site, Clinton, South Carolina, United States Regeneron Study Site, Amarillo, Texas, United States Regeneron Study Site, Corpus Christi, Texas, United States Regeneron Study Site, Houston, Texas, United States Regeneron Study Site, Houston, Texas, United States Regeneron Study Site, Houston, Texas, United States Regeneron Study Site, Houston, Texas, United States Regeneron Study Site, Pearland, Texas, United States Regeneron Study Site, Red Oak, Texas, United States Regeneron Study Site, San Antonio, Texas, United States Regeneron Study Site, Splendora, Texas, United States Regeneron Study Site, Tyler, Texas, United States Regeneron Study Site, Falls Church, Virginia, United States |
1796 | Not yet recruiting | COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19 | COVID-19 | Drug: casirivimab+imdevimab | Phase 1 | Regeneron Pharmaceuticals | INDUSTRY | 40 | All | ~ 17 Years | |
1795 | Active, not recruiting | COVID-19 Study of Safety and Tolerability of Alvelestat | Covid19 | Drug: Alvelestat Drug: Placebo |
Phase 2 | University of Alabama at Birmingham, Mereo BioPharma | OTHER | 15 | All | 18 Years | UAB Lung Health Center, Birmingham, Alabama, United States |